Cargando…

Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program

CCR2 is the cognate receptor to the chemokine CCL2. CCR2–CCL2 signaling mediates cancer progression and metastasis dissemination. However, the role of CCR2–CCL2 signaling in pathogenesis of B-cell malignancies is not clear. Previously, we showed that CCR2B was upregulated in ex vivo peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozireva, Svetlana, Rudevica, Zhanna, Baryshev, Mikhail, Leonciks, Ainars, Kashuba, Elena, Kholodnyuk, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977232/
https://www.ncbi.nlm.nih.gov/pubmed/29751565
http://dx.doi.org/10.3390/v10050239
_version_ 1783327335623163904
author Kozireva, Svetlana
Rudevica, Zhanna
Baryshev, Mikhail
Leonciks, Ainars
Kashuba, Elena
Kholodnyuk, Irina
author_facet Kozireva, Svetlana
Rudevica, Zhanna
Baryshev, Mikhail
Leonciks, Ainars
Kashuba, Elena
Kholodnyuk, Irina
author_sort Kozireva, Svetlana
collection PubMed
description CCR2 is the cognate receptor to the chemokine CCL2. CCR2–CCL2 signaling mediates cancer progression and metastasis dissemination. However, the role of CCR2–CCL2 signaling in pathogenesis of B-cell malignancies is not clear. Previously, we showed that CCR2B was upregulated in ex vivo peripheral blood B cells upon Epstein‒Barr virus (EBV) infection and in established lymphoblastoid cell lines with the EBV latency III program. EBV latency III is associated with B-cell lymphomas in immunosuppressed patients. The majority of EBV-positive Burkitt lymphoma (BL) tumors are characterized by latency I, but the BL cell lines drift towards latency III during in vitro culture. In this study, the CCR2A and CCR2B expression was assessed in the isogenic EBV-positive BL cell lines with latency I and III using RT-PCR, immunoblotting, and immunostaining analyses. We found that CCR2B is upregulated in the EBV-positive BL cells with latency III. Consequently, we detected the migration of latency III cells toward CCL2. Notably, the G190A mutation, corresponding to SNP CCR2-V64I, was found in one latency III cell line with a reduced migratory response to CCL2. The upregulation of CCR2B may contribute to the enhanced migration of malignant B cells into CCL2-rich compartments.
format Online
Article
Text
id pubmed-5977232
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-59772322018-06-01 Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program Kozireva, Svetlana Rudevica, Zhanna Baryshev, Mikhail Leonciks, Ainars Kashuba, Elena Kholodnyuk, Irina Viruses Brief Report CCR2 is the cognate receptor to the chemokine CCL2. CCR2–CCL2 signaling mediates cancer progression and metastasis dissemination. However, the role of CCR2–CCL2 signaling in pathogenesis of B-cell malignancies is not clear. Previously, we showed that CCR2B was upregulated in ex vivo peripheral blood B cells upon Epstein‒Barr virus (EBV) infection and in established lymphoblastoid cell lines with the EBV latency III program. EBV latency III is associated with B-cell lymphomas in immunosuppressed patients. The majority of EBV-positive Burkitt lymphoma (BL) tumors are characterized by latency I, but the BL cell lines drift towards latency III during in vitro culture. In this study, the CCR2A and CCR2B expression was assessed in the isogenic EBV-positive BL cell lines with latency I and III using RT-PCR, immunoblotting, and immunostaining analyses. We found that CCR2B is upregulated in the EBV-positive BL cells with latency III. Consequently, we detected the migration of latency III cells toward CCL2. Notably, the G190A mutation, corresponding to SNP CCR2-V64I, was found in one latency III cell line with a reduced migratory response to CCL2. The upregulation of CCR2B may contribute to the enhanced migration of malignant B cells into CCL2-rich compartments. MDPI 2018-05-03 /pmc/articles/PMC5977232/ /pubmed/29751565 http://dx.doi.org/10.3390/v10050239 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Kozireva, Svetlana
Rudevica, Zhanna
Baryshev, Mikhail
Leonciks, Ainars
Kashuba, Elena
Kholodnyuk, Irina
Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program
title Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program
title_full Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program
title_fullStr Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program
title_full_unstemmed Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program
title_short Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program
title_sort upregulation of the chemokine receptor ccr2b in epstein‒barr virus-positive burkitt lymphoma cell lines with the latency iii program
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977232/
https://www.ncbi.nlm.nih.gov/pubmed/29751565
http://dx.doi.org/10.3390/v10050239
work_keys_str_mv AT kozirevasvetlana upregulationofthechemokinereceptorccr2binepsteinbarrviruspositiveburkittlymphomacelllineswiththelatencyiiiprogram
AT rudevicazhanna upregulationofthechemokinereceptorccr2binepsteinbarrviruspositiveburkittlymphomacelllineswiththelatencyiiiprogram
AT baryshevmikhail upregulationofthechemokinereceptorccr2binepsteinbarrviruspositiveburkittlymphomacelllineswiththelatencyiiiprogram
AT leonciksainars upregulationofthechemokinereceptorccr2binepsteinbarrviruspositiveburkittlymphomacelllineswiththelatencyiiiprogram
AT kashubaelena upregulationofthechemokinereceptorccr2binepsteinbarrviruspositiveburkittlymphomacelllineswiththelatencyiiiprogram
AT kholodnyukirina upregulationofthechemokinereceptorccr2binepsteinbarrviruspositiveburkittlymphomacelllineswiththelatencyiiiprogram